CJC-1295 without DAC 5mg/vial,10vials/kit

Product Description

Modified GRF (Growth Releasing Factor) 1-29, sometimes referred to as CJC-1295 no DAC, is a synthetic GHRH (Growth Hormone Releasing Hormone). Naturally occurring GHRH has forty-four amino acids in its structure. Sermorelin, sometimes referred to as Modified GRF (1-29), has twenty nine amino acids in its structure. Unlike Sermorelin, four of the amino acids in the structure of Modified GRF (1-29) have been replaced in order to avoid oxidation and deterioration in the manufacturing and storage process. Additionally, the Modified GRF (1-29) will not metabolize rapidly in plasma.

Purity, Formulation & Physical Appearance

GHPeptides™ Modified GRF (1-29) has a peptide purity level that exceeds 99.0% as determined by HPLC. This peptide was synthesized with no additives and is supplied as a white lyophilized (freeze-dried) powder.

Solubility & Storage

It is recommended to reconstitute the lyophilized Modified GRF (1-29) in sterile water, which can then be further diluted in other aqueous solutions. Lyophilized Modified GRF (1-29) although stable at room temperature for 3-4 weeks, should be stored desiccated below -18°C. Upon reconstitution, Modified GRF (1-29) should be stored at 4°C out of direct light for between 10-14 days and for future use below -18°C. Prevent repeated freeze-thaw cycles.

Product Usage

This product has been synthesized for in-vitro laboratory studies to be performed with cells or biological molecules. This product is not a drug and has not been approved by the FDA to prevent or cure any medical condition or disease. The purchaser is solely liable for risk involved with using this product for any purpose outside of in vitro studies.

Modified GRF (1-29) often abbreviated as mod GRF (1-29), originally known as tetrasubstituted GRF (1-29), is a term used to identify a 29 amino acid peptide analogue of growth-hormone-releasing hormone (GHRH), a releasing hormone of growth hormone (GH). It is a modified version of the shortest fully functional fragment of GHRH, often referred to as growth hormone releasing factor (1-29) (abbreviated as GRF (1-29)), and also known by its standardized name, sermorelin.

Origin

The first 29 amino acids of GHRH were discovered to be as equally potent as its full 44 amino acid structure^[1][2] This fragment became known as GRF (1-29). However, due to a rapid metabolic clearance analogues of GRF (1-29) were synthesized to enhance the biological activity and reduce the rapidity of metabolic clearance. These analogues were primarily created by substituting amino acids within the peptide structure for amino acids more resistant to enzymatic cleavage. One early analogue substituted the amino acid L-alanine (abbreviated as Ala or A) at the 2nd position of the peptide structure for its optical isomer (mirror image), D-alanine (abbreviated as D-Ala). This substitution resulted in a peptide bond between D-Ala and the 3rd amino acid in the structure aspartic acid (Asp) more able to resist rapid cleavage by the enzyme dipeptidyl peptidase-4, a cleavage which had previously led to an inactive peptide fragment.^[3][4] This successful modification prompted the further creation of analogues with additional amino acid substitutions.

In 2005, the first specific mention of tetrasubstituted GRF (1-29) appeared in a study that used it as one of the GRF (1-29) analogue peptide structures studied.^[5] The term was used to describe the replacement of the 2nd, 8th, 15th, and 27th amino acids in the structure of GRF (1-29).

In 2008, a researcher known as DatBtrue created the term modified GRF (1-29) in place of tetrasubstitued GRF (1-29) in his public articles. Continued use of the term on public and private forums has popularized and standardized the nomenclature.